Status:
COMPLETED
Biomarker and DNA Collection in Subjects Participating in Protocol 22003
Lead Sponsor:
Seaside Therapeutics, Inc.
Conditions:
Fragile X Syndrome
Eligibility:
All Genders
6-17 years
Brief Summary
The subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22003 will be offered participation in 22003A which will evaluate secreted protein before and after t...
Eligibility Criteria
Inclusion
- The Autism Spectrum Disorder subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22003
Exclusion
- The Autism Spectrum Disorder subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22003
Key Trial Info
Start Date :
May 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00892580
Start Date
May 1 2009
Last Update
July 31 2013
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Southwest Autism Research & Resource Center
Phoenix, Arizona, United States, 85006
2
University of California-Los Angeles Neuropsychiatric Institute
Los Angeles, California, United States, 90024
3
Yale Child Study Center
New Haven, Connecticut, United States, 06520
4
Riley Hospital for Children
Indianapolis, Indiana, United States, 46202